Quantum BioPharma Ltd. (QNTM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Quantum BioPharma Ltd. (QNTM) has a cash flow conversion efficiency ratio of -0.229x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.72 Million) by net assets ($7.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See QNTM net asset quality index to measure how much of total assets are equity-financed.
Quantum BioPharma Ltd. - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Quantum BioPharma Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Quantum BioPharma Ltd. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Quantum BioPharma Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quantum BioPharma Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vesuvius PLC
LSE:VSVS
|
0.074x |
|
Investcorp Credit Management BDC Inc
NASDAQ:ICMB
|
0.196x |
|
Tecnisa S.A
SA:TCSA3
|
0.020x |
|
Horseshoe Metals Ltd
AU:HOR
|
0.151x |
|
BOA Resources Ltd
AU:BOA
|
-0.089x |
|
Origin Agritech Ltd
F:39O1
|
N/A |
|
Amalgamated Industrial Steel Berhad
KLSE:2682
|
-0.152x |
|
Reborn Coffee Inc
NASDAQ:REBN
|
0.105x |
Annual Cash Flow Conversion Efficiency for Quantum BioPharma Ltd. (2015–2024)
The table below shows the annual cash flow conversion efficiency of Quantum BioPharma Ltd. from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see QNTM stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $10.44 Million | $-6.88 Million | -0.659x | +21.47% |
| 2023-12-31 | $12.91 Million | $-10.83 Million | -0.839x | +9.59% |
| 2022-12-31 | $30.54 Million | $-28.33 Million | -0.928x | -142.05% |
| 2021-12-31 | $54.13 Million | $-20.75 Million | -0.383x | +27.26% |
| 2020-12-31 | $36.31 Million | $-19.13 Million | -0.527x | -39.39% |
| 2019-12-31 | $36.28 Million | $-13.71 Million | -0.378x | -4.33% |
| 2018-12-31 | $37.47 Million | $-13.58 Million | -0.362x | -2901.16% |
| 2017-12-31 | $9.87 Million | $-119.18K | -0.012x | -102.41% |
| 2016-12-31 | $-54.30K | $-27.24K | 0.502x | +46056.13% |
| 2015-12-31 | $-58.37K | $-63.44 | 0.001x | -- |
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in d… Read more